The first patient has been dosed in a phase 1/2 trial evaluating treatment with AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2, for patients with ...

The data will showcase the potential of AP402, a first-in-class, next generation T cell engager targeting CD137 and p95HER2 in in-vivo and in vitro studies. AP402 recently received IND clearance ...

AP402 is constructed using T-cube bispecific antibody technology which combines p95HER2 targeting with a CD137 activation domain to enable target-dependent T-cell activation exclusively in the ...